18422250. METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN simplified abstract (NEC Corporation)
Contents
- 1 METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN
Organization Name
Inventor(s)
Brandon Malone of Heidelberg (DE)
METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN - A simplified explanation of the abstract
This abstract first appeared for US patent application 18422250 titled 'METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN
Simplified Explanation
The computer-implemented method described in the abstract involves selecting amino acid sequences for inclusion in a vaccine based on their ability to elicit an immune response. This is done by analyzing immune profile response values for candidate amino acid sequences and selecting those that minimize the likelihood of no immune response across representative immune profiles for a population.
- Identifying immune profile response values for candidate amino acid sequences
- Generating representative immune profiles for a population
- Selecting amino acid sequences for inclusion in a vaccine based on immune profile response values
Potential Applications
This technology could be applied in the development of vaccines for various diseases by selecting the most effective amino acid sequences to include in the vaccine formulation.
Problems Solved
This technology helps in optimizing vaccine design by selecting amino acid sequences that are more likely to elicit an immune response, thus improving the effectiveness of the vaccine.
Benefits
The benefits of this technology include improved vaccine efficacy, potentially leading to better protection against diseases, and a more targeted approach to vaccine development.
Potential Commercial Applications
One potential commercial application of this technology could be in the pharmaceutical industry for the development of vaccines against infectious diseases.
Possible Prior Art
One possible prior art for this technology could be the use of computational methods to predict immunogenic epitopes for vaccine development.
What is the impact of this technology on vaccine development?
This technology has the potential to revolutionize vaccine development by enabling the selection of the most effective amino acid sequences for inclusion in vaccines, leading to improved immune responses and better protection against diseases.
How does this method compare to traditional vaccine development approaches?
This method offers a more targeted and efficient approach to vaccine development by leveraging computational analysis to select the most promising amino acid sequences for inclusion in vaccines. Traditional approaches may rely more on empirical testing and trial-and-error methods.
Original Abstract Submitted
A computer-implemented method of selecting one or more amino acid sequences for inclusion in a vaccine from a set of predicted immunogenic candidate amino acid sequences includes identifying an immune profile response value for each candidate amino acid sequence with respect to each one of a plurality of sample components of an immune profile. The immune profile response value represents whether the respective candidate amino acid sequence results in an immune response for the sample components of the immune profile. A plurality of immune profiles are retrieved for a population. A plurality of representative immune profiles are generated for the population. The representative immune profiles overlap with the sample components of the immune profiles. The one or more amino acid sequences for inclusion in the vaccine that minimises a likelihood of no immune response for each representative immune profile, based on the immune profile response values, are selected.
